Global Pharmaceutical CDMO 2.0 Market to Reach $272.85 Billion by 2031 as Biologics and Complex Drug Pipelines Expand
Dublin, Aug. 20, 2026 (GLOBE NEWSWIRE) -- The "Pharmaceutical CDMO 2.0 - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ResearchAndMarkets.com's offering.
The global pharmaceutical CDMO 2.0 market is projected to grow from USD 173.55 billion in 2025 to USD 186.65 billion in 2026. By 2031, the market is forecast to reach USD 272.85 billion, representing a compound annual growth rate of 7.89% from 2026 to 2031. Growth is being supported by increased pharmaceutical research and development spending, greater outsourcing activity, expanding biologics pipelines, and demand for flexible, technology-enabled manufacturing capacity.
Pharmaceutical Outsourcing Gains Momentum
Large pharmaceutical companies are increasingly outsourcing non-core and early-stage development activities to partners with advanced chemistry, manufacturing, and controls expertise. Milestone-based agreements, co-investment structures, and multi-year capacity reservations are providing CDMOs with more predictable revenue while enabling drug developers to reduce fixed-asset exposure.
Demand remains particularly strong for flexible, mid-scale capacity that can adapt to clinical attrition and changing production requirements. Pharmaceutical companies are also consolidating supplier networks to improve quality oversight, regulatory compliance, and operational efficiency. This trend favors CDMOs capable of supporting projects from early development through commercial manufacturing.
Biologics and Complex Molecules Drive Capacity Investment
Antibody-drug conjugates, therapeutic peptides, cell and gene therapies, mRNA products, and other advanced modalities are becoming increasingly prominent in clinical pipelines. These products require specialized manufacturing infrastructure, advanced containment systems, and complex analytical capabilities, reducing the number of qualified service providers and supporting premium pricing.
Samsung Biologics commissioned Plant 5 in 2025, increasing its installed capacity to 784,000 liters, and is evaluating further expansion to address anticipated demand. Meanwhile, shortages in high-titer lentiviral vector and mRNA production are encouraging sponsors to reserve manufacturing suites well ahead of potential commercial launches.
Highly potent active pharmaceutical ingredients are also expected to generate strong growth, supported by demand for antibody-drug conjugate payloads and metabolic peptides. Stringent occupational exposure requirements restrict production to facilities with advanced containment capabilities, strengthening the position of experienced CDMOs.
Regulatory Requirements Reshape Supplier Selection
Increasingly stringent requirements across the United States, Europe, and Asia are raising compliance costs and influencing pharmaceutical outsourcing decisions. The U.S. Food and Drug Administration's Quality Management System Regulation takes effect in February 2026, requiring combination-product manufacturers to align documentation with ISO 13485.
In Europe, updated Annex 1 contamination-control requirements are driving substantial facility investments, while expanded stability-testing expectations in Japan are adding analytical costs and extending approval timelines. Pharmaceutical sponsors increasingly favor CDMOs with established multi-region licenses, validated quality systems, and the resources to maintain compliance across multiple regulatory jurisdictions.
Finished-Dosage Manufacturing Records Strong Growth
Finished-dosage development and manufacturing is forecast to expand at a 9.01% CAGR, making it one of the fastest-growing areas of the pharmaceutical CDMO 2.0 market. Competition for pre-filled syringe, vial, and sterile manufacturing capacity remains intense, with lead times ranging from 12 to 24 months in some areas.
API development and manufacturing accounted for 61.09% of the market in 2025 and continues to represent the industry's largest service category. However, margins face pressure as pharmaceutical companies adopt dual-sourcing strategies to reduce geopolitical and supply chain risks.
Analytical testing, packaging, and logistics services are also gaining importance. Regulatory agencies are requesting more extensive stability and release-testing packages, while serialization requirements are supporting demand for specialized packaging capabilities. Emerging biotechnology companies without large internal manufacturing teams are especially reliant on CDMOs for formulation, analytical development, and clinical-stage support.
Capacity shortages are encouraging sponsors to sign multi-year take-or-pay agreements that secure access to isolators, automated visual inspection systems, and sterile production lines. Providers combining fill-finish, secondary packaging, and cold-chain logistics can offer more efficient commercialization pathways and generate higher revenue per production batch.
Small Molecules Lead as Advanced Modalities Accelerate
Small-molecule programs represented 65.21% of the pharmaceutical CDMO 2.0 market in 2025, reflecting sustained demand for orally administered therapies. Growth is shifting toward highly potent APIs, which are forecast to expand at an 8.12% CAGR. Specialized analytical services, including drug-to-antibody ratio testing, are creating additional revenue opportunities for qualified suppliers.
Large-molecule manufacturing is also benefiting from significant capacity additions. AGC Biologics plans to bring 5,000-liter single-use reactors online in 2027, while other providers continue investing in mammalian expression, mRNA, and viral-vector platforms. CDMOs able to redeploy suites across multiple technologies are positioned to improve utilization and broaden client relationships.
Regional Pharmaceutical CDMO 2.0 Market Outlook
North America generated 40.25% of global revenue in 2025. Regional growth is supported by supply chain localization, advanced manufacturing investment, and demand for data-rich production services. FUJIFILM is developing a USD 3.2 billion biologics and mRNA campus in Holly Springs, North Carolina, scheduled to become operational in 2028. Resilience has also added USD 225 million in peptide manufacturing capacity at its Ohio facility.
Europe continues to invest in sterile manufacturing, lyophilization, potent oral-dose production, and contamination-control upgrades. The revised Annex 1 requirements are increasing capital expenditure while creating more consistent standards for technology transfers across European facilities.
Asia-Pacific is forecast to record the fastest regional CAGR of 9.78% through 2031. South Korea is expanding large-scale biologics capacity, while Indian CDMOs are benefiting from supply chain diversification by Western pharmaceutical companies. Japan is strengthening advanced mammalian manufacturing capabilities, and Singapore and Malaysia continue to attract investment through stable policies and tax incentives. Multinational sponsors are also adopting China-plus-one sourcing strategies to reduce concentration risk.
South America's pharmaceutical outsourcing activity remains centered on Brazil, where regulatory alignment with International Council for Harmonisation guidelines is improving market access. Regional initiatives to expand local fill-finish capacity may reduce import dependence, although limited cold-chain infrastructure continues to constrain biologics distribution.
Key Topics Covered
1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Outsourcing Volume by Large Pharmaceutical Companies
4.2.2 Surge in Biologics and Complex-Molecule Pipelines
4.2.3 Cost- and Speed-Advantage of Manufacturing in Emerging Markets
4.2.4 Consolidation Toward End-to-End One-Stop CDMOs
4.2.5 AI-Enabled Rapid Process-Development Platforms
4.2.6 GLP-1 and Peptide HPAPI Capacity Build-Outs
4.3 Market Restraints
4.3.1 Stringent Multi-Region Regulatory Requirements
4.3.2 Capacity-Utilization and Lead-Time Risk
4.3.3 High Capex for Sterile Biologics Suites
4.3.4 Scarcity of Skilled Aseptic-Manufacturing Talent
4.4 Value / Supply-Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter's Five Forces Analysis
4.7.1 Threat of New Entrants
4.7.2 Bargaining Power of Suppliers
4.7.3 Bargaining Power of Buyers
4.7.4 Threat of Substitutes
4.7.5 Competitive Rivalry
5 Market Size & Growth Forecasts
5.1 By Service
5.1.1 API Development & Manufacturing
5.1.2 Finished-Dosage Development & Manufacturing
5.1.3 Analytical & Testing Services
5.1.4 Packaging & Logistics
5.1.5 Other Services
5.2 By Molecule Type
5.2.1 Small Molecule
5.2.2 Large Molecule / Biologics
5.2.3 Highly-Potent APIs
5.3 By Development Phase
5.3.1 Pre-clinical
5.3.2 Phase I
5.3.3 Phase II
5.3.4 Phase III
5.3.5 Commercial
5.4 By End User
5.4.1 Large Pharma
5.4.2 Emerging / Venture-backed Biotech
5.4.3 Generics / Specialty Pharma
5.4.4 Virtual Pharma & Tech-bio
5.5 By Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 United Kingdom
5.5.2.2 Germany
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 India
5.5.3.3 Japan
5.5.3.4 South Korea
5.5.3.5 Australia
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East and Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East and Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global level Overview, Market level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
6.3.1 Aenova Group
6.3.2 AGC Biologics
6.3.3 Almac
6.3.4 Asymchem Inc.
6.3.5 Boehringer Ingelheim International GmbH.
6.3.6 Cambrex Corporation
6.3.7 Curia Global, Inc.
6.3.8 FUJIFILM Biotechnologies.
6.3.9 Lonza Group AG
6.3.10 Novo Holdings A/S (Catalent Inc.)
6.3.11 Piramal Pharma Solutions
6.3.12 Recipharm AB (EQT AB)
6.3.13 Rentschler Biopharma
6.3.14 Samsung Biologics
6.3.15 Siegfried Holding AG
6.3.16 Sterling Pharma Solutions
6.3.17 Thermo Fisher Scientific Inc. (Patheon)
6.3.18 Vetter Pharma
6.3.19 WuXi Biologics
6.3.20 Sterling Pharma Solutions
7 Market Opportunities & Future Outlook
7.1 White-space & Unmet-Need Assessment
For more information about this report visit https://www.researchandmarkets.com/r/7blr8l
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.